This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 High-Volume Stocks With Relative Strength

Questcor Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Questcor Pharmaceuticals (QCOR) is a biopharmaceutical company. Questcor's primary product is H.P. Acthar Gel (repository corticotropin injection) (Acthar), an injectable drug that is approved by the U.S. Food and Drug Administration, for the treatment of 19 indications. This stock is trading up 10.4% at $55.49 in recent trading.

Today's Volume: 4.5 million

Average Volume: 1.85 million

Volume % Change: 306%

Shares of QCOR are skyrocketing today after the company reported strong second-quarter sales of its flagship multiple sclerosis drug Acthar. The company shipped 4,710 vials of Acthar for Apirl to June, which represented a 15% rise from the previous quarter.

>>22 Biopharma Stocks With Breakout Potential in 2012

From a technical perspective, QCOR is gapping up huge with monster volume. This gap-up has pushed QCOR into breakout territory, since the stock has moved above some near-term overhead resistance at $54.31. At last check, QCOR has hit an intraday high of $58.91 and the volume is well above its three-month average action of 1.85 million shares. Amazingly, this move has yet to push QCOR into extremely overbought territory since its current relative strength index reading is just 69.25.

Traders should now look for long-biased trades once QCOR breaks out above today's high of $58.91 with strong volume. Look for a sustained move or close above $58.91 with volume that's near or above 1.85 million shares. Traders can also look for long-trades as long as QCOR is trending above that key breakout point of $54.31.

Questcor shows up on a list of Hot Biotech Stocks Traded by Hedge Funds in the most recently reported quarter.

3 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs